Bleeding News and Research

RSS

Antithrombotic therapy increases bleeding risk in CAD patients: Research

Antithrombotic therapy using antiplatelet and anticoagulant agents is the cornerstone of treatment for acute and chronic coronary artery disease (CAD), yet it is also associated with an increased risk of bleeding. It is paradoxical that elderly patients, the most likely population to develop CAD, are those that suffer most from bleeding complications.

31 Aug 2010

$Heparin enoxaparin may provide better outcomes than unfractionated heparin$

Heparin enoxaparin may provide better outcomes than unfractionated heparin

Results from ATOLL, a phase 3 randomised trial comparing two anticoagulants in primary PCI for ST elevation MI, show that the low molecular weight heparin enoxaparin may provide better outcomes in such cases than the traditionally used unfractionated heparin.

30 Aug 2010

Nihon-Kohden granted exclusive rights to distribute Z-Medica's QuikClot line of hemostatic agents in Japan

Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced that it has signed an exclusive distribution agreement with Nihon-Kohden, Japan's leading manufacturer, developer and distributor of medical electronic equipment . The agreement allows Nihon-Kohden the exclusive right to distribute Z-Medica's QuikClot line of hemostatic agents to hospital, military and law enforcement markets throughout Japan. The companies have been working together since early 2009 to obtain regulatory approval.

From Medica Corporation 30 Aug 2010

Boehringer Ingelheim announces sub-analysis result of RE-LY trial

Boehringer Ingelheim today announced results from a pre-specified, retrospective, un-blinded sub-analysis of the RE-LY trial the largest atrial fibrillation outcomes trial ever conducted were published in The Lancet.

30 Aug 2010

ATOLL study favors enoxaparin over UFH for primary Percutaneous Coronary Intervention

The international ATOLL study sponsored by the Assistance Publique - Hopitaux de Paris showed that enoxaparin reduced the composite of death, complication of myocardial infraction, procedure failure or major bleeding by 17% in comparison with standard heparin death, recurrent acute coronary syndrome or urgent revascularisation. The results of the ATOLL study were presented at the hotline session of the annual European Cardiology Congress (ESC 2010) in Stockholm, Sweden.

30 Aug 2010

Jefferson scientists receive grant to study genetics of platelet gene expression

Scientists at Jefferson Medical College have received a four-year, $3 million National Institutes of Health grant funded by the National Heart, Lung and Blood Institute to study variations of platelet function, specifically, the genetics of platelet gene expression. The study aims to find data that can be translated into novel therapeutic strategies and develop better predictors of cardiovascular disease.

30 Aug 2010

Eight signs of cancer: Study

Scientists have now identified eight signs of cancer that need immediate attention. These can predict the risk of cancer with such accuracy in certain age groups that patients should be referred to a specialist straight away unless there is a good explanation that is is something else.

30 Aug 2010

Study reveals impact of genetic make-up on response to oral antiplatelet treatment ticagrelor

A new genetic substudy of PLATO showed that the effects on a combined primary endpoint of cardiovascular death, myocardial infarction, or stroke seen in Acute Coronary Syndromes patients who received the investigational oral antiplatelet treatment, ticagrelor (BRILINTA), were maintained, whether or not they had the genetic variability that has been previously shown to affect a patient's response to clopidogrel.

30 Aug 2010

Practice guideline-recommended care reduces bleeding in cirrhosis patients

Compliance with practice guideline-recommended treatment for cirrhosis is associated with a reduction in first esophageal variceal hemorrhage (EVH; bleeding), according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

26 Aug 2010

Sermo report highlights physician opinions about investigational oral antiplatelet treatment for ACS

Sermo, the world's largest online community for physicians, today announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome.

26 Aug 2010

Veteran Affairs to use Redsense alarm to detect blood leakage during hemodialysis

The Redsense alarm will be required for use in Veteran Affairs' dialysis centers. The safety alert, based on research from Veteran Affairs National Center for Patient Safety, marks an important step for the only alarm that detects blood leakage during hemodialysis.

26 Aug 2010

Researchers to test new plantain based food product to treat Crohn's disease

Crohn's is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to pain, bleeding and diarrhoea. Researchers are working with biotechnology company, Provexis, to test a new plantain based food product that could treat patients with the disease.

26 Aug 2010

Synovis Life Technologies third-quarter net revenue increases 17% to $17.6 million

Synovis Life Technologies, Inc., today reported its financial results for the third quarter ended July 31, 2010.

25 Aug 2010

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.

25 Aug 2010

Migraine with aura increases risk of heart disease: Research

Individuals who suffer from migraines with aura (temporary visual or sensory disturbances before or during a migraine headache) are at a higher risk of dying from heart disease or stroke.

25 Aug 2010

Adoption of standby intra-aortic balloon pump strategy during high-risk PCI needed: Study

High-risk patients undergoing a coronary procedure such as placement of a stent who electively received an intra-aortic balloon pump (a device that can help improve blood flow) prior to the procedure did not experience a significantly lower overall rate of events such as heart attack, revascularization or death, according to a study in the August 25 issue of JAMA.

25 Aug 2010

Study finds rectal cancer rates are increasing among young individuals

A new analysis has found that while colon cancer rates have remained steady over the past several decades among people under the age of 40, rectal cancer rates are increasing in this population across races and in both sexes.

23 Aug 2010

Fenwal's new software release for Autopheresis-C system receives FDA 510(k) clearance

Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market a new software release for its Autopheresis-C® system. Blood and plasma centers worldwide use the Autopheresis-C system to collect plasma from donors.

20 Aug 2010

Study finds no clinical benefits from gender-specific total knee prostheses for women

A gender-specific total knee prosthesis was developed to more closely match the anatomy of the female knee, aiming to be a better fit resulting in better outcomes for women. However, a recent study in the Journal of Bone and Joint Surgery (JBJS) found that 85 women who received a gender-specific implant in one knee and a standard prosthesis in the other knee found no clinical benefits of the gender-specific knee.

19 Aug 2010

Scientists identify possible therapeutic strategy for reducing leukemia risk from chemotherapy

A UCSF-led team has discovered at least one key reason why blood stem cells are susceptible to developing the genetic mutations that can lead to adult leukemia. Their finding also may explain, they say, why some other age-related hematological disorders develop.The study, reported in "Cell Stem Cell" and reviewed in Cell Stem Cell and Cell, opens a new frontier for studying the molecular underpinnings of adult leukemia.

17 Aug 2010

Bleeding News and Research

Antithrombotic therapy increases bleeding risk in CAD patients: Research

Heparin enoxaparin may provide better outcomes than unfractionated heparin

Nihon-Kohden granted exclusive rights to distribute Z-Medica's QuikClot line of hemostatic agents in Japan

Boehringer Ingelheim announces sub-analysis result of RE-LY trial

ATOLL study favors enoxaparin over UFH for primary Percutaneous Coronary Intervention

Jefferson scientists receive grant to study genetics of platelet gene expression

Eight signs of cancer: Study

Study reveals impact of genetic make-up on response to oral antiplatelet treatment ticagrelor

Practice guideline-recommended care reduces bleeding in cirrhosis patients

Sermo report highlights physician opinions about investigational oral antiplatelet treatment for ACS

Veteran Affairs to use Redsense alarm to detect blood leakage during hemodialysis

Researchers to test new plantain based food product to treat Crohn's disease

Synovis Life Technologies third-quarter net revenue increases 17% to $17.6 million

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Migraine with aura increases risk of heart disease: Research

Adoption of standby intra-aortic balloon pump strategy during high-risk PCI needed: Study

Study finds rectal cancer rates are increasing among young individuals

Fenwal's new software release for Autopheresis-C system receives FDA 510(k) clearance

Study finds no clinical benefits from gender-specific total knee prostheses for women

Scientists identify possible therapeutic strategy for reducing leukemia risk from chemotherapy

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News